Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal (IP) therapy for patients with gynecologic malignancies.

IP therapy is a treatment with a demonstrated overall survival (OS) benefit, Muggia explains. However, it has not gained enough traction to become a go-to treatment. A recent study published in the Journal of Clinical Oncology showed that IP therapy should be used in ovarian cancer when optimal cytoreduction leads to minimal residual disease.

The published study also reported that there is an OS benefit with IP therapy, with a 25% hazard ratio for reduction of deaths.

View more from the 2015 CFS Annual Meeting

Videos

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies. 

Franco Muggia, MD

Articles

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers